8-K Announcements
6Material company update
May 20, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Apr 24, 2026·SEC
Telomir Pharmaceuticals, Inc. Common Stock(TELO)Earnings, Financials & Key Ratios
TELO•NASDAQ
$1.30
Price updated Jul 7, 2026
AboutTelomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. It develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy recovery by interrupting and preventing the interleukin-17 induced inflammatory pathways. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. on October 10, 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.Show more
- Revenue$0
- EBITDA-$11M
- Net Income-$10M+37.0%
- EPS (Diluted)-0.33+41.1%
- ROE-317.65%+60.8%
TELO Price & Volume
Telomir Pharmaceuticals, Inc. Common Stock (TELO) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Threatens Clinical Development Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Binary clinical trial failure
Key Thesis Takeaways
- Telomir Pharmaceuticals remains in a high-risk, pre-clinical stage characterized by significant quarterly operating losses and a total absence of revenue generation.
- The company's reliance on $8.3 million in stock-based compensation during 2024 and 2025 suggests a strategy to preserve liquidity, yet the rapid erosion of the asset base to $5.8 million as of 2026Q1 raises concerns regarding long-term solvency.
- Investors should monitor the company's ability to secure non-dilutive funding, as the current cash position appears insufficient to support the capital-intensive requirements of future human clinical trials.
Verdict Logic
the company's inability to generate revenue combined with a rapid decline in total assets from $7.4 million in 2025Q3 to $5.8 million in 2026Q1 suggests an unsustainable financial trajectory.
TELO Growth Metrics
Telomir Pharmaceuticals, Inc. Common Stock (TELO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM26.31%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM30.02%
Return on Capital
10 Years-412.22%
5 Years-412.22%
3 Years-412.22%
Last Year-321.48%
Peers Comparison
Key metrics vs top competitors for Telomir Pharmaceuticals, Inc. Common Stock (TELO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.30 | $44.7M | -3.94 | — | — | -317.65% | — | |
| $4.04 | $155.9M | -3.01 | — | — | -38.7% | — | |
| $0.00 | $117 | — | -97.62% | -362385.72% | — | — | |
| $7.41 | $92.58M | -29.64 | 14.52% | -9.05% | -70.95% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $1.32 | $329.07M | -4.71 | 53.24% | -434.44% | -156.65% | — |
Compare TELO vs Peers
Telomir Pharmaceuticals, Inc. Common Stock (TELO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TELO SEC Filings & Documents
Telomir Pharmaceuticals, Inc. Common Stock (TELO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when TELO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TELO Frequently Asked Questions
Telomir Pharmaceuticals, Inc. Common Stock (TELO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is TELO profitable?
Telomir Pharmaceuticals, Inc. Common Stock (TELO) reported a net loss of $9.2M for fiscal year 2025.
Dividend & Returns
What is TELO's return on equity?
Telomir Pharmaceuticals, Inc. Common Stock (TELO) has a return on equity (ROE) of -317.6%. Negative ROE indicates the company is unprofitable.
What is Telomir Pharmaceuticals, Inc. Common Stock's free cash flow?
Telomir Pharmaceuticals, Inc. Common Stock (TELO) had negative free cash flow of $4.6M in fiscal year 2025, likely due to heavy capital investments.